Morgan Stanley Aclaris Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,415,584 shares of ACRS stock, worth $3.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,415,584

Previous 1,071,784 125.38%

Holding current value

$3.77 Million

Previous $2.66 Million 39.01%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.53 - $2.6 $2.06 Million - $3.49 Million	1,343,800 Added 125.38%	2,415,584 $3.7 Million
Q4 2024 Feb 14, 2025	BUY	$1.15 - $4.59 $679,662 - $2.71 Million	591,011 Added 122.93%	1,071,784 $2.66 Million
Q3 2024 May 14, 2025	BUY	$1.12 - $1.4 $329,761 - $412,202	294,430 Added 158.0%	480,773 $543,000
Q3 2024 Nov 14, 2024	BUY	$1.12 - $1.4 $329,761 - $412,202	294,430 Added 158.0%	480,773 $543,000
Q2 2024 May 14, 2025	SELL	$1.01 - $1.36 $894,295 - $1.2 Million	-885,441 Reduced 82.61%	186,343 $204,000
Q2 2024 Oct 17, 2024	SELL	$1.01 - $1.36 $308,376 - $415,239	-305,323 Reduced 62.1%	186,343 $204,000
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $308,376 - $415,239	-305,323 Reduced 62.1%	186,343 $204,000
Q1 2024 Oct 17, 2024	BUY	$0.92 - $1.44 $280,897 - $439,665	305,323 Added 163.85%	491,666 $609,000
Q1 2024 Aug 16, 2024	SELL	$0.92 - $1.44 $445,475 - $697,266	-484,213 Reduced 49.62%	491,666 $609,000
Q1 2024 May 15, 2024	SELL	$0.92 - $1.44 $445,475 - $697,266	-484,213 Reduced 49.62%	491,666 $609,000
Q4 2023 Aug 16, 2024	BUY	$0.64 - $6.49 $505,303 - $5.12 Million	789,536 Added 423.7%	975,879 $1.02 Million
Q4 2023 Feb 13, 2024	SELL	$0.64 - $6.49 $462,407 - $4.69 Million	-722,512 Reduced 42.54%	975,879 $1.02 Million
Q3 2023 Nov 15, 2023	BUY	$6.56 - $10.95 $417,058 - $696,157	63,576 Added 3.89%	1,698,391 $11.6 Million
Q2 2023 Aug 14, 2023	BUY	$7.89 - $10.64 $7.56 Million - $10.2 Million	958,197 Added 141.62%	1,634,815 $17 Million
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $3.79 Million - $9.63 Million	536,214 Added 381.91%	676,618 $5.47 Million
Q4 2022 Feb 14, 2023	SELL	$14.33 - $18.37 $392,756 - $503,484	-27,408 Reduced 16.33%	140,404 $2.21 Million
Q3 2022 Nov 14, 2022	BUY	$13.07 - $18.22 $87,595 - $122,110	6,702 Added 4.16%	167,812 $2.64 Million
Q2 2022 Oct 27, 2022	BUY	$10.16 - $17.08 $1.32 Million - $2.22 Million	130,171 Added 420.73%	161,110 $2.25 Million
Q2 2022 Aug 15, 2022	BUY	$10.16 - $17.08 $1.32 Million - $2.22 Million	130,171 Added 420.73%	161,110 $2.25 Million
Q1 2022 Oct 27, 2022	SELL	$9.74 - $17.92 $1.27 Million - $2.33 Million	-130,171 Reduced 80.8%	30,939 $532,000
Q1 2022 May 13, 2022	SELL	$9.74 - $17.92 $116,198 - $213,785	-11,930 Reduced 27.83%	30,939 $532,000
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $127,571 - $192,240	10,397 Added 32.02%	42,869 $623,000
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $434,475 - $610,473	32,472 New	32,472 $585,000

Others Institutions Holding ACRS

# of Institutions

112

Shares Held

92.9M

Call Options Held

35.4K

Put Options Held

32K

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $104M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account